DermTech (OTC: DMTK)
DermTech Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
DermTech Company Info
DermTech's Pigmented Lesion Assay (PLA) offers a noninvasive approach that greatly improves accuracy in detecting early-stage melanoma.
News & Analysis
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run
This beaten-down healthcare stock has started the new year off with a bang.
Will These Two Stocks Boom or Bust?
These two stocks have sky-high potential.
Should You Sell DermTech and GoodRx Stocks Right Now?
Only if your underlying premise for buying the stocks has changed from when you initially bought them.
Why DermTech Still Has Ten-Bagger Potential
Skin-cancer detection could lead to big returns for this stock.
This Is the Main Problem With DermTech's Q3 Results
Nothing major changed for the skin genomics company in Q3.
3 Stocks to Watch Closely This Earnings Season
One Motley Fool contributor especially has his eyes on quarterly updates for these healthcare stocks.
3 Things About DermTech That Smart Investors Know
These three facts can help you determine whether you want in on this fast-growing company.
3 Stocks That Could Double Your Money Sooner Than You Think
These stocks have what it takes to deliver 100% returns in five years or less.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.